Monte Rosa Therapeutics GLUE
NASDAQ GLUE
$11.14 -0.22 (-1.94%)
As of: Oct 21, 2026 · 3:11 PM EDT

Monte Rosa Therapeutics (GLUE) Receivables - Net (2024)

Updated

Monte Rosa Therapeutics' Receivables - Net came in at $9 million for Q2 2024.

Analysis

Monte Rosa Therapeutics (GLUE) Receivables - Net (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.62 Bn 1,105.21 Bn 19.71 Bn
2 Johnson & Johnson 617.59 Bn 536.12 Bn 17.26 Bn
3 AbbVie 501.69 Bn 474.80 Bn 12.70 Bn
4 Merck 368.29 Bn 322.67 Bn 12.21 Bn
5 Novartis Ag 297.79 Bn 261.78 Bn 11.24 Bn
6 Astrazeneca 260.82 Bn 234.50 Bn 12.86 Bn
7 Amgen 236.53 Bn 191.93 Bn 7.24 Bn
8 Gilead Sciences 191.14 Bn 165.33 Bn 6.22 Bn
9 Pfizer 169.69 Bn 116.33 Bn 10.94 Bn
10 Monte Rosa Therapeutics 1.13 Bn 541.27 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2024 9.00 Mn
API Access

Monte Rosa Therapeutics Receivables - Net API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-net&ticker=GLUE&period=max&api_key=YOUR_API_KEY